iFluor® 488 goat anti-mouse IgG (H+L) Cross Adsorbed

Ordering information

Price
Catalog Number
Unit Size
Quantity

Add to cart

Additional ordering information

Telephone	1-800-990-8053
Fax	1-800-609-2943
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Shipping	Standard overnight for United States, inquire for international

Physical properties

Molecular weight	~150000
Solvent	Water

Spectral properties

Correction Factor (260 nm)	0.21
Correction Factor (280 nm)	0.11
Extinction coefficient (cm ^-1 M ^-1)	75000¹
Excitation (nm)	491
Emission (nm)	516
Quantum yield	0.9¹

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22
Storage	Freeze (< -15 °C); Minimize light exposure
UNSPSC	12171501

Alternative formats

Overview SDS Protocol

Molecular weight

~150000

Correction Factor (260 nm)

0.21

Correction Factor (280 nm)

0.11

Extinction coefficient (cm ^-1 M ^-1)

75000¹

Excitation (nm)

491

Emission (nm)

516

Quantum yield

0.9¹

AAT Bioquest's iFluor® dyes are optimized for labeling proteins, in particular, antibodies. These dyes are bright, photostable and have minimal quenching on proteins. They can be well excited by the major laser lines of fluorescence instruments (e.g., 350, 405, 488, 555 and 633 nm). iFluor® 488 goat anti-mouse IgG (H+L) conjugate has fluorescence excitation and emission maxima of ~491 nm and ~514 nm respectively. These spectral characteristics make them an excellent alternative to Alexa Fluor® 488 goat anti-mouse IgG (H+L) conjugate (Alexa Fluor® is the trademark of Invitrogen).

Spectrum

Open in Advanced Spectrum Viewer

Spectral properties

Correction Factor (260 nm)	0.21
Correction Factor (280 nm)	0.11
Extinction coefficient (cm ^-1 M ^-1)	75000¹
Excitation (nm)	491
Emission (nm)	516
Quantum yield	0.9¹

Product Family

Name	Excitation (nm)	Emission (nm)	Extinction coefficient (cm ^-1 M ^-1)	Quantum yield	Correction Factor (260 nm)	Correction Factor (280 nm)
iFluor® 350 goat anti-mouse IgG (H+L)	345	450	20000¹	0.95¹	0.83	0.23
iFluor® 405 goat anti-mouse IgG (H+L)	403	427	37000¹	0.91¹	0.48	0.77
iFluor® 514 goat anti-mouse IgG (H+L)	511	527	75000¹	0.83¹	0.265	0.116
iFluor® 532 goat anti-mouse IgG (H+L)	537	560	90000¹	0.68¹	0.26	0.16
iFluor® 555 goat anti-mouse IgG (H+L)	557	570	100000¹	0.64¹	0.23	0.14
iFluor® 594 goat anti-mouse IgG (H+L)	588	604	180000¹	0.53¹	0.05	0.04
iFluor® 633 goat anti-mouse IgG (H+L)	640	654	250000¹	0.29¹	0.062	0.044
iFluor® 647 goat anti-mouse IgG (H+L)	656	670	250000¹	0.25¹	0.03	0.03
iFluor® 680 goat anti-mouse IgG (H+L)	684	701	220000¹	0.23¹	0.097	0.094
iFluor® 700 goat anti-mouse IgG (H+L)	690	713	220000¹	0.23¹	0.09	0.04
iFluor® 750 goat anti-mouse IgG (H+L)	757	779	275000¹	0.12¹	0.044	0.039
iFluor® 790 goat anti-mouse IgG (H+L)	787	812	250000¹	0.13¹	0.1	0.09
iFluor® 350 goat anti-mouse IgG (H+L) Cross Adsorbed	345	450	20000¹	0.95¹	0.83	0.23
iFluor® 405 goat anti-mouse IgG (H+L) Cross Adsorbed	403	427	37000¹	0.91¹	0.48	0.77
iFluor® 514 goat anti-mouse IgG (H+L) Cross Adsorbed	511	527	75000¹	0.83¹	0.265	0.116
iFluor® 532 goat anti-mouse IgG (H+L) Cross Adsorbed	537	560	90000¹	0.68¹	0.26	0.16
iFluor® 555 goat anti-mouse IgG (H+L) Cross Adsorbed	557	570	100000¹	0.64¹	0.23	0.14
iFluor® 594 goat anti-mouse IgG (H+L) Cross Adsorbed	588	604	180000¹	0.53¹	0.05	0.04
iFluor® 633 goat anti-mouse IgG (H+L) Cross Adsorbed	640	654	250000¹	0.29¹	0.062	0.044
iFluor® 647 goat anti-mouse IgG (H+L) Cross Adsorbed	656	670	250000¹	0.25¹	0.03	0.03
iFluor® 680 goat anti-mouse IgG (H+L) Cross Adsorbed	684	701	220000¹	0.23¹	0.097	0.094
iFluor® 700 goat anti-mouse IgG (H+L) Cross Adsorbed	690	713	220000¹	0.23¹	0.09	0.04
iFluor® 750 goat anti-mouse IgG (H+L) Cross Adsorbed	757	779	275000¹	0.12¹	0.044	0.039
iFluor® 790 goat anti-mouse IgG (H+L) Cross Adsorbed	787	812	250000¹	0.13¹	0.1	0.09
iFluor® 488 goat anti-rabbit IgG (H+L)	491	516	75000¹	0.9¹	0.21	0.11
iFluor® 488 goat anti-rabbit IgG (H+L) Cross Adsorbed	491	516	75000¹	0.9¹	0.21	0.11
iFluor® 546 goat anti-mouse IgG (H+L)	541	557	100000¹	0.67¹	0.25	0.15
iFluor® 546 goat anti-mouse IgG (H+L) Cross Adsorbed	541	557	100000¹	0.67¹	0.25	0.15
iFluor® 568 goat anti-mouse IgG (H+L)	568	587	100000¹	0.57¹	0.34	0.15
iFluor® 568 goat anti-mouse IgG (H+L) Cross Adsorbed	568	587	100000¹	0.57¹	0.34	0.15
iFluor® 800 goat anti-mouse IgG (H+L)	801	820	250000¹	0.11¹	0.03	0.08
iFluor® 800 goat anti-mouse IgG (H+L) Cross Adsorbed	801	820	250000¹	0.11¹	0.03	0.08
iFluor® 810 goat anti-mouse IgG (H+L)	811	822	250000¹	0.05¹	0.09	0.15
iFluor® 810 goat anti-mouse IgG (H+L) Cross Adsorbed	811	822	250000¹	0.05¹	0.09	0.15
iFluor® 820 goat anti-mouse IgG (H+L)	822	850	250000¹		0.11	0.16
iFluor® 820 goat anti-mouse IgG (H+L) Cross Adsorbed	822	850	250000¹		0.11	0.16
iFluor® 840 goat anti-mouse IgG (H+L)	836	879	200000¹	-	0.2	0.09
iFluor® 840 goat anti-mouse IgG (H+L) Cross Adsorbed	836	879	200000¹	-	0.2	0.09
iFluor® 860 goat anti-mouse IgG (H+L)	853	878	250000¹		0.1	0.14
iFluor® 860 goat anti-mouse IgG (H+L) Cross Adsorbed	853	878	250000¹		0.1	0.14
Show More (31)

Images

Figure 1. HeLa cells were incubated with (Tubulin+) or without (Tubulin-) mouse anti-tubulin followed by iFluor® 488 goat anti-mouse IgG conjugate (Green, Left) or Alexa Fluor® 488 goat anti-mouse IgG conjugate (Green, Right), respectively. Cell nuclei were stained with Hoechst 33342 (Blue).

Citations

View all 13 citations: Citation Explorer

Rab11-FIP4 interacts with ARF5 to promote cancer stemness in hepatocellular carcinoma
Authors: Song, Feifeng and Zhang, Qi and Lu, Xixuan and Xu, Tong and Hu, Qing and Hu, Xiaoping and Fan, Weijiao and Zhang, Yiwen and Huang, Ping
Journal: Journal of Physiology and Biochemistry (2023): 1--14

Upregulation of HMGB1 in tumor-associated macrophages induced by tumor cell-derived lactate further promotes colorectal cancer progression
Authors: Gao, Xinyi and Zhou, Shiqi and Qin, Zhaofu and Li, Dechuan and Zhu, Yuping and Ma, Dening
Journal: Journal of Translational Medicine (2023): 1--13

Oxidative stress biomarker triggered multiplexed tool for auxiliary diagnosis of atherosclerosis
Authors: Ma, Yuan and Sun, Wei and Ye, Zhifei and Liu, Liuhui and Li, Menghuan and Shang, Jinhui and Xu, Xinyu and Cao, Hui and Xu, Li and Liu, Yongchao and others,
Journal: Science Advances (2023): eadh1037

Liensinine Inhibits Mitophagy to Potentiate Mitochondria-Targeting Artemisinin-Loaded Polymer Nanostructures for Breast Cancer Therapy
Authors: Li, Jia-Mi and Yu, Hui and Deng, Kai and Wang, Qian and Li, Kun-Heng and Huang, Shi-Wen
Journal: ACS Applied Nano Materials (2023)

Enhancement of pacing function by HCN4 overexpression in human pluripotent stem cell-derived cardiomyocytes
Authors: Saito, Yukihiro and Nakamura, Kazufumi and Yoshida, Masashi and Sugiyama, Hiroki and Akagi, Satoshi and Miyoshi, Toru and Morita, Hiroshi and Ito, Hiroshi
Journal: Stem Cell Research \& Therapy (2022): 1--13

The Bioactive Phenolic Agents Diaryl Ether CVB2-61 and Diarylheptanoid CVB4-57 as Connexin Hemichannel Blocker
Authors: Dierks, Anne and Vanucci-Bacqu{\'e}, Corinne and Sch{\"a}fer, Anne-Marie and Lehrich, Tina and Ruhe, Frederike and Schadzek, Patrik and Bedos-Belval, Florence and Ngezahayo, Anaclet
Journal: (2022)

Multifunctional Metal--Organic Framework Exoskeletons Protect Biohybrid Sperm Microrobots for Active Drug Delivery from the Surrounding Threats
Authors: Chen, Qiwei and Tang, Songsong and Li, Yangyang and Cong, Zhaoqing and Lu, Dongdong and Yang, Qingxin and Zhang, Xueji and Wu, Song
Journal: ACS Applied Materials \& Interfaces (2021): 58382--58392

Stimulation of the A
Authors: Connexin26, Receptor Subtype Enhances
Journal: Cell Physiol Biochem (2019): 606--622

Phospholipase Cγ2 is critical for Ca 2+ flux and cytokine production in anti-fungal innate immunity of human corneal epithelial cells
Authors: Peng, Xudong and Zhao, Guiqiu and Lin, Jing and Qu, Jianqiu and Zhang, Yingxue and Li, Cui
Journal: BMC ophthalmology (2018): 170

Overexpression of CXCR2 predicts poor prognosis in patients with colorectal cancer.
Authors: Zhao, Jingkun and Ou, Baochi and Feng, Hao and Wang, Puxiongzhi and Yin, Shuai and Zhu, Congcong and Wang, Shenjie and Chen, Chun and Zheng, Minhua and Zong, Yaping and others, undefined
Journal: Oncotarget (2017)

References

View all 191 references: Citation Explorer

Antiprothrombin antibodies in a patient with secondary antiphospholipid syndrome and bleeding
Authors: Gonzalez Leon R, Garcia Hern and ez FJ, Castillo Palma MJ, Sanchez Roman J.
Journal: Med Clin (Barc) (2011): 668

Assessment of EGFR/HER2 dimerization by FRET-FLIM utilizing Alexa-conjugated secondary antibodies in relation to targeted therapies in cancers
Authors: Waterhouse BR, Gijsen M, Barber PR, Tullis ID, Vojnovic B, Kong A.
Journal: Oncotarget (2011): 728

Falsely elevated tacrolimus levels caused by immunoassay interference secondary to beta-galactosidase antibodies in an infected liver transplant recipient
Authors: Knorr JP, Grewal KS, Balasubramanian M, Young N, Zaki R, Khanmoradi K, Araya V, Ortiz J.
Journal: Pharmacotherapy (2010): 954

Prevalence of anti-Epstein-Barr virus antibodies in children and adolescents with secondary immunodeficiency
Authors: Buckova A., undefined
Journal: Epidemiol Mikrobiol Imunol (2010): 133

Analysis of the effectiveness of reused primary and secondary antibodies in Western blotting analysis
Authors: Boonrod K, Roth B, Leong Ngar S, Krczal G.
Journal: Anal Biochem (2010): 124

Nanosilver-doped DNA polyion complex membrane for electrochemical immunoassay of carcinoembryonic antigen using nanogold-labeled secondary antibodies
Authors: Wu W, Yi P, He P, Jing T, Liao K, Yang K, Wang H.
Journal: Anal Chim Acta (2010): 126

Three siblings with self-resolving congenital hyperthyrotropinaemia secondary to thyrotropin receptor blocking antibodies
Authors: Azzopardi P, Forrester M, Ehtisham S.
Journal: J Paediatr Child Health (2010): 439

Double-blotting: a solution to the problem of nonspecific binding of secondary antibodies in immunoblotting procedures
Authors: Lasne F., undefined
Journal: Methods Mol Biol (2009): 213

Parkinsonism/dystonia syndrome secondary to multiple sclerosis with anti-basal-ganglia antibodies
Authors: Delgado S, Baez S, Singer C, Sengun C, Sheremata WA, Papapetropoulos S.
Journal: Mov Disord (2009): 309

Neutralizing antibodies and secondary therapy failure after treatment with botulinum toxin type A: much ado about nothing
Authors: Lange O, Bigalke H, Dengler R, Wegner F, deGroot M, Wohlfarth K.
Journal: Clin Neuropharmacol (2009): 213